Kevan Clifford Herold MD

Endocrinology•New Haven, CT

Diabetes, Lipid Metabolism

Professor, Immunobiology, Yale University School of Medicine

Join to View Full Profile

789 Howard Avenue 2nd FloorDana BuildingNew Haven, CT 06510

Education & Training

University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1986
Temple University HospitalResidency, Internal Medicine, 1979 - 1982
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1979

Certifications & Licensure

CT State Medical License 2006 - 2025
NY State Medical License 1998 - 2025
IL State Medical License 1982 - 1999
PA State Medical License 1981 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

TrialNet Pathway to Prevention of T1D Start of enrollment: 2004 Feb 01
Recruiting
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes Start of enrollment: 2005 Sep 01
Completed
Phase 2
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes Start of enrollment: 2006 Sep 01
Completed
Phase 2
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Start of enrollment: 2007 Feb 01
Completed
Phase 3
Treatment With hOKT3gamma1(Ala-Ala) in T1DM Start of enrollment: 2002 May 01
Terminated
Phase 2
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" Start of enrollment: 2010 Aug 01
Completed
Phase 2
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II Start of enrollment: 2010 Oct 01
Withdrawn
Phase 2
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs Start of enrollment: 2010 Nov 01
Completed
Phase 1
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Start of enrollment: 2013 Mar 01
Completed
Phase 2
Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes Start of enrollment: 2012 Jan 01
Completed
Phase 1
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Start of enrollment: 2013 Sep 01
Completed
Phase 2
AbATE Follow-Up Study Start of enrollment: 2014 Feb 01
Completed
Type 1 Diabetes Extension Study Start of enrollment: 2016 Aug 18
RECRUITING
T1DM Immunotherapy Using Polyclonal Tregs + IL-2 Start of enrollment: 2016 Aug 01
Completed
Phase 1
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) Start of enrollment: 2018 Oct 24
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.
Zoe Quandt, Ana Perdigoto, Mark S Anderson, Kevan C Herold
Cold Spring Harbor Perspectives in Medicine. 2025-04-01
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.
Alfonso Galderisi, Emily K Sims, Carmella Evans-Molina, Alessandra Petrelli, David Cuthbertson
Diabetologia. 2025-03-01
Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.
Maria J Redondo, David Cuthbertson, Andrea K Steck, Kevan C Herold, Richard Oram
Diabetologia. 2025-03-01

Journal Articles

A Call for Improved Reporting of Human Islet Characteristics in Research Articles
Steven E Kahn, Kevan C Herold, Maureen Gannon, Diabetologia
Identification and Analysis of Islet Antigen–Specific CD8+ T Cells with T Cell Libraries
Kevan C Herold, Andrea K Steck, The Journal of Immunology
Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting
Neil Romberg, Antoni Ribas, Michael R Lee, Ruby Yu, Gary M Kupfer, Julia Carnevale, Jonathan H Esensten, P Jonathan Li, Han Li, Kevan C Herold, Alexander Marson, Nature
Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors
Robert Rushakoff, Zoe Quandt, James Lee, Kevan C Herold, Diabetes Care
Join now to see all

Lectures

Abnormal Neutrophil Signature in the Blood and Pancreas of Presymptomatic and Symptomatic Type 1 Diabetes
New Haven, CT - 6/15/2014

Press Mentions

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes MellitusFebruary 24th, 2025
In a 1st, Scientists Reversed Type 1 Diabetes by Reprogramming a Person's Own Fat CellsOctober 31st, 2024
5 Medical Advances That Will Change Patient CareMay 4th, 2023
Join now to see all

Grant Support

Modulating pathogenic T cells in Type 1 diabetesYALE UNIVERSITY2000–2029
Modulating pathogenic T cells in Type 1 diabetesYALE UNIVERSITY2000–2029
Modulating pathogenic T cells in Type 1 diabetesYALE UNIVERSITY2000–2029
Diabetes Mellitus and Disorders of MetabolismYALE UNIVERSITY1975–2029
Diabetes Mellitus and Disorders of MetabolismYALE UNIVERSITY1975–2029
Diabetes Mellitus and Disorders of MetabolismYALE UNIVERSITY1975–2029
Diabetes Mellitus and Disorders of MetabolismYALE UNIVERSITY1975–2029
Yale Diabetes Research CenterYALE UNIVERSITY1997–2028
Advanced pancreatic-immune organoid models of type 1 diabetes subtypes and therapeutic responsesYALE UNIVERSITY2025–2026
Human and Translational Immunology Training ProgramYALE UNIVERSITY2021–2026
Human and Translational Immunology Training ProgramYALE UNIVERSITY2021–2026
Human and Translational Immunology Training ProgramYALE UNIVERSITY2021–2026
Human and Translational Immunology Training ProgramYALE UNIVERSITY2021–2026
Human and Translational Immunology Training ProgramYALE UNIVERSITY2021–2026
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetesYALE UNIVERSITY2021–2025
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetesYALE UNIVERSITY2021–2025
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetesYALE UNIVERSITY2021–2025
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetesYALE UNIVERSITY2021–2025
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetesYALE UNIVERSITY2021–2025
Human And Translational ImmunologyNational Institute Of Allergy And Infectious Diseases2010–2011
Type 1 Diabetes Trialnet: Clinical Center At Yale University (U01)National Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Yale Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2009–2011
Administrative Core A, Component Of Yale Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2009–2011
Innate And Adaptive Immune Responses In Pre-Type 1 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2010
Type 1 Diabetes Trialnet: Clinical Center At Columbia UniversityNational Institute Of Diabetes And Digestive And Kidney Diseases2007
Type 1 Diabetes Trialnet: Clin Ctr At Columbia Universi*National Institute Of Diabetes And Digestive And Kidney Diseases2006
Islet Growth In NOD Mice Tolerant To Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2005
Safety And PK Of Hokt3yl (Ala-Ala) In TidmNational Center For Research Resources2005
Islet Transplants With Renal AllograftsNational Center For Research Resources2005
Islet Growth In NOD Mice Tolerant To Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
Combination Of Anti-Cd3 And Ag-Specific ImmunotherapyNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
Phase II Multiple Dose Treatment Of Type 1 Diabetes Mellitus With Hokt3gammalNational Center For Research Resources2004–2005
Hokt3yl(Ala-Ala) In New Onset Type 1 Diabetes MellitusNational Center For Research Resources2004–2005
Type 1 Diabetes Trialnet: Clin Ctr At Columbia Universi*National Institute Of Diabetes And Digestive And Kidney Diseases2002–2005
Hokt3yl (Ala Ala) In New Onset Type I Diabetes MellitusNational Center For Research Resources2000–2002
T Cell Activation And Repertoire In Insulin Dependent Diabetes / Anti CD40L TrialNational Institute Of Allergy And Infectious Diseases1999–2002
Type 1 Diabetes Trialnet:Columbia UniversityNational Institute Of Diabetes And Digestive And Kidney Diseases2001
Clinical Research Training In Immunosuppression And DiabNational Center For Research Resources2000
Diabetes Prevention Trial--Type I DiabetesNational Center For Research Resources1996–1997
Immunoregulation Of IDDMNational Institute Of Diabetes And Digestive And Kidney Diseases1995
Islet Cell Reactive T-Lymphocytes In DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1994
Immune Mechanism For Preventing Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1994
Islet Cell Reactive T Lymphocytes In Murine DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1993